Bard Financial Services Inc. Raises Stock Position in GSK PLC Sponsored ADR $GSK

Bard Financial Services Inc. increased its position in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 17.4% in the 3rd quarter, HoldingsChannel reports. The fund owned 158,145 shares of the pharmaceutical company’s stock after acquiring an additional 23,400 shares during the period. Bard Financial Services Inc.’s holdings in GSK were worth $6,826,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of GSK. Trust Co. of Toledo NA OH grew its holdings in GSK by 2.1% in the third quarter. Trust Co. of Toledo NA OH now owns 31,455 shares of the pharmaceutical company’s stock worth $1,358,000 after purchasing an additional 650 shares during the last quarter. Farther Finance Advisors LLC boosted its position in shares of GSK by 73.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 11,976 shares of the pharmaceutical company’s stock worth $517,000 after purchasing an additional 5,053 shares in the last quarter. TOWER TRUST & INVESTMENT Co grew its stake in GSK by 1.3% during the 3rd quarter. TOWER TRUST & INVESTMENT Co now owns 23,195 shares of the pharmaceutical company’s stock worth $1,001,000 after buying an additional 293 shares during the last quarter. First Bank & Trust grew its stake in GSK by 61.5% during the 3rd quarter. First Bank & Trust now owns 51,151 shares of the pharmaceutical company’s stock worth $2,208,000 after buying an additional 19,484 shares during the last quarter. Finally, First County Bank CT acquired a new position in GSK during the 3rd quarter valued at about $220,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Price Performance

Shares of NYSE GSK opened at $49.10 on Friday. The company has a debt-to-equity ratio of 0.95, a current ratio of 0.84 and a quick ratio of 0.55. The stock has a market capitalization of $100.09 billion, a price-to-earnings ratio of 13.87, a PEG ratio of 1.33 and a beta of 0.45. The firm’s 50 day simple moving average is $47.31 and its 200-day simple moving average is $42.40. GSK PLC Sponsored ADR has a 12 month low of $31.72 and a 12 month high of $49.44.

GSK (NYSE:GSK) last posted its earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.26 by $0.22. The firm had revenue of $11.35 billion for the quarter, compared to analysts’ expectations of $8.21 billion. GSK had a return on equity of 48.64% and a net margin of 17.16%.The company’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period last year, the firm earned $0.50 EPS. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. Analysts expect that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 8th. Stockholders of record on Friday, November 14th will be given a $0.4171 dividend. The ex-dividend date is Friday, November 14th. This represents a $1.67 dividend on an annualized basis and a dividend yield of 3.4%. GSK’s payout ratio is 46.05%.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Wall Street Zen raised GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, September 5th. HSBC reaffirmed a “reduce” rating on shares of GSK in a research report on Wednesday, December 10th. Bank of America raised shares of GSK from an “underperform” rating to a “neutral” rating in a research report on Tuesday, November 25th. Jefferies Financial Group restated a “buy” rating on shares of GSK in a research note on Monday, October 27th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of GSK in a research note on Monday, December 22nd. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $44.13.

Insider Buying and Selling at GSK

In other GSK news, major shareholder Plc Gsk bought 1,470,000 shares of GSK stock in a transaction dated Thursday, December 11th. The stock was acquired at an average cost of $19.00 per share, with a total value of $27,930,000.00. Following the purchase, the insider directly owned 18,245,691 shares in the company, valued at $346,668,129. This represents a 8.76% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 10.00% of the stock is currently owned by insiders.

GSK Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.